TrialCNS drugs2024

A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial.

John M Kane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.